In the last trading session, 3.92 million Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) shares changed hands as the company’s beta touched 0.95. With the company’s per share price at $0.54 changed hands at $0.01 or 0.98% during last session, the market valuation stood at $194.37M. LXRX’s last price was a discount, traded about -353.7% off its 52-week high of $2.45. The share price had its 52-week low at $0.28, which suggests the last value was 48.15% up since then.
Analysts gave the Lexicon Pharmaceuticals Inc (LXRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LXRX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Lexicon Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.08.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Instantly LXRX was in green as seen at the end of in last trading. With action -23.65%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -27.53%, with the 5-day performance at -23.65% in the red. However, in the 30-day time frame, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is 7.04% up.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 91.0% from its current market value. According to analyst projections, LXRX’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -1011.11% plunge from its current level, while the stock would need to soar -1011.11% for it to hit the projected low.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
Year-over-year growth is forecast to reach -55.50% down from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 4.87M. 4 analysts are of the opinion that Lexicon Pharmaceuticals Inc’s revenue for the current quarter will be 4.92M. The company’s revenue for the corresponding quarters a year ago was 1.65M and 1.75M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 195.54%. The estimates for the next quarter sales put growth at 181.14%.
The 2025 estimates are for Lexicon Pharmaceuticals Inc earnings to increase by 49.60%, but the outlook for the next 5-year period is at 30.30% per year.
LXRX Dividends
Lexicon Pharmaceuticals Inc is expected to release its next quarterly earnings report in June.
FMR LLC holds the second largest percentage of outstanding shares, with 12.4462% or 38.69 million shares worth $64.99 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 10.16 shares estimated at $5.44 million under it, the former controlled 2.80% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 1.42% of the shares, roughly 5.15 shares worth around $2.75 million.
